Zentalis Pharmaceuticals (ZNTL) Cash & Equivalents (2019 - 2026)

Zentalis Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $31.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 23.85% year-over-year to $31.9 million in Q1 2026; TTM through Mar 2026 was $31.9 million, a 23.85% decrease from a year earlier, with the FY2025 full-year figure at $36.0 million, up 6.18% from the prior year.
• Cash & Equivalents retreated to $31.9 million in Q1 2026 per ZNTL's latest filing, from $36.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $266.6 million in Q2 2023 and bottomed at $28.0 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $37.6 million (2024), against an average of $55.8 million.
• Across the five-year window, Cash & Equivalents surged 383.39% in 2023 and sank 86.13% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $43.1 million in 2022, then plunged by 34.9% to $28.0 million in 2023, then advanced by 20.91% to $33.9 million in 2024, then climbed by 6.18% to $36.0 million in 2025, then slipped by 11.29% to $31.9 million in 2026.
• Per Business Quant, the three latest ZNTL Cash & Equivalents figures stand at $31.9 million (Q1 2026), $36.0 million (Q4 2025), and $39.1 million (Q3 2025).